Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Asthma Data Prompts Pulmagen To Seek Global Partner For CRTh2 Antagonist

Executive Summary

Following positive Phase II data from its CRTh2 antagonist PTR-36 in eosinophilic asthma patients, Pulmagen is looking for a late-stage development partner. PTR-36 is administered at a dose 'an order of magnitude lower' than a competing program from Novartis which is in Phase III, said the small UK firm.

Advertisement

Related Content

Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Teijin turns to Pulmagen to plug respiratory pipeline gap

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel